Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Steven I. Park1, Jaideep Shenoi2,3, Shani M. Frayo2, Donald K. Hamlin4, Yukang Lin2, D. Scott Wilbur4, Patrick S. Stayton5, Nural Orgun2, Mark Hylarides2, Franz Buchegger6, Aimee L. Kenoyer2, Amanda Axtman2, Ajay K. Gopal2,3, Damian J. Green2,3, John M. Pagel2,3, and Oliver W. Press2,3

Abstract

Purpose: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, "endogenous" biotin can interfere with the effectiveness of this approach by blocking binding of radiolabeled biotin to SAv. We engineered a series of SAv FPs that downmodulate the affinity of SAv for biotin, while retaining high avidity for divalent DOTA-bis-biotin to circumvent this problem.

Experimental Design: The single-chain variable region gene of the murine 1F5 anti-CD20 antibody was fused to the wild-type (WT) SAv gene and to mutant SAv genes, Y43A-SAv and S45A-SAv. FPs were expressed, purified, and compared in studies using athymic mice bearing Ramos lymphoma xenografts.

Results: Biodistribution studies showed delivery of more radioactivity to tumors of mice pretargeted with mutant SAv FPs followed by 111In-DOTA-bis-biotin [6.2 ± 1.7% of the injected dose per gram (%ID/gm) of tumor 24 hours after Y43A-SAv FP and 5.6 ± 2.2%ID/g with S45A-SAv FP] than in mice on normal diets pretargeted with WT-SAv FP (2.5 ± 1.6%ID/g; P = 0.01). These superior biodistributions translated into superior antitumor efficacy in mice treated with mutant FPs and 90Y-DOTA-bis-biotin [tumor volumes after 11 days: 237 ± 66 mm3 with Y43A-SAv, 543 ± 320 mm3 with S45A-SAv, 1129 ± 322 mm3 with WT-SAv, and 1435 ± 212 mm3 with control FP (P < 0.0001)].

Conclusions: Genetically engineered mutant-SAv FPs and bis-biotin reagents provide an attractive alternative to current SAv-biotin PRIT methods in settings where endogenous biotin levels are high.

Clin Cancer Res; 17(23); 7373–82. ©2011 AACR.
resultant high levels of background radioactivity in normal tissues (11–13). Pretargeted radioimmunotherapy (PRIT) dissociates the slow distribution phase of the Ab molecule from administration of the therapeutic radionuclide. This approach permits the tumor-reactive Ab to localize and accumulate at tumor sites without subjecting the rest of the body to nonspecific irradiation from circulating radiolabeled Ab (14–17). After maximal accumulation of Ab in the tumor, a small molecular weight radioactive moiety, which has high affinity for the tumor-reactive Ab is administered. This second reagent penetrates tumors rapidly due to its small size. Excess unbound molecules of the second radioactive reagent are also rapidly cleared from the blood and excreted in the urine due to their small size. To facilitate this process, a “clearing agent” (CA) may be injected before the radiolabeled small molecule to enhance elimination of the unbound Ab from the bloodstream thus preventing it from complexing with the radiolabeled small molecule in the circulation.

Preclinical data have shown that streptavidin (SAv)-biotin pretargeting strategies can dramatically increase the tumor-to-normal organ ratio of delivered radioactivity by 10- to 100-fold (16–18). Pilot clinical trials have also shown promising results in both solid tumor and lymphoma models, though the outcomes were not as dramatic as those observed in preclinical studies (19–22). Suboptimal responses observed in the pilot clinical trials may be partially attributable to the presence of competing endogenous biotin in patient serum, derived from dietary sources. Biotin is present in blood and tissues at sufficient concentrations to irreversibly block the biotin-binding sites of SAv and may impair its efficacy in pretargeting applications (21, 23). In preclinical studies, mice may be fed a biotin-deficient diet for several days prior to the therapy to reduce the endogenous biotin concentration in serum. In contrast, biotindepletion in human clinical trials is more problematic due to the ubiquitous presence of this vitamin in all common foods, patient noncompliance, and concerns over complications attributable to biotin deficiency. Although the serum concentration of biotin present in humans is somewhat lower than in mice, endogenous biotin remains a significant concern, particularly because the liver acts as a storage and release reservoir for biotin (24). Strategies that avoid the blocking of the biotin-binding sites of SAv by endogenous biotin may therefore offer therapeutic advantages. To address this issue, Stayton and colleagues produced a large library of SAv variants by site-directed mutagenesis directed at the SAv-binding pocket (Supplementary Table S1), covering a wide range of Ks and Koff properties (25–26). Along with the engineering of SAv mutants, divalent bis-biotin ligands were designed to effectively engage 2 adjacent biotin-binding sites of SAv mutants, thus overcoming the competitive binding by endogenous biotin (27–29). The lower affinities and faster biotin off-rates of the SAv mutants allow exchange of prebound endogenous biotin, although the dual binding of the bis-biotin ligand results in a striking avidity effect and essentially irreversible capture of the modified divalent ligand (27, 30–32). In this manuscript, we describe the synthesis and characterization of 2 SAv mutant fusion proteins (FP), S45A-SAv and Y43A-SAv. The FPs were selected based on previous kinetic studies suggesting they were the most promising candidates that would allow exchange of prebound monovalent endogenous biotin while retaining sufficiently high affinity to efficiently capture radiolabeled divalent bis-biotin ligands (27, 29). We report here the blood clearance of the mutant-SAv FPs using a standard monovalent biotin CA or a novel bivalent biotin CA, specifically designed for this application. Finally, we compare the targeting, biodistributions, and therapeutic efficacy of PRIT strategies utilizing either conventional wild type (WT)-SAv and biotin or mutant-SAv and bis-biotin reagent combinations.

Materials and Methods

Cell culture

The human Ramos Burkitt lymphoma cell line was obtained from the American Type Culture Collection (ATCC). Cell lines were maintained in log phase growth in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum in a 5% CO2 incubator. Cell viability exceeded 95% by trypan blue exclusion.

WT-SAv FP and mutant-SAv FPs

The development of the 1F5-WT-SAv FP has been previously described (33–35). Briefly, the process involved fusion of the single-chain variable regions (scFv) of the murine anti-CD20 1F5 Ab to the full length genomic SAv of Streptomyces avidinii WT gene to obtain the 1F5(scFv)SAv fusion gene. This gene construct was modified by PCR-based site-directed mutagenesis to produce mutant genes.

Translational Relevance

Conventional radioimmunotherapy (RIT) induces long-term durable remissions in more than 50% of patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Our research goal is to optimize RIT using a multistep pretargeted RIT scheme (PRIT) employing genetically engineered mutant-streptavidin fusion proteins and bis-biotin reagents that provide an attractive alternative to current methods. This molecular engineering approach is particularly attractive in clinical settings where high endogenous biotin levels prevail due to dietary intake of this vitamin, leading to diminished efficacy of standard streptavidin/biotin reagents.

We anticipate that this approach will result in superior efficacy compared with both conventional RIT and current PRIT approaches. If the results are promising, we anticipate eventually translating this approach into phase I/II clinical studies of PRIT for patients with relapsed B-cell lymphomas.
carrying either the S45A or the Y43A mutations, with an SSGSGSA peptide linker between the SA and the scFv genes in each construct. The residue changes in fusion genes were determined by DNA sequencing analysis, and the gene products were analyzed by mass spectroscopy, which indicated all FPs differed only at the deliberately engineered positions without any extraneous mutations (data not shown). E. coli XL1 Blue (Stratagene) transformants of the gene constructs, WT-SAv, S45A-SAv, or Y43A-SAv, were grown in shaker flasks under control of an IPTG inducible lac promoter for qualitative expression of the FPs. A 4 L fermentor (BioFlo 3000; New Brunswick Scientific) was used for bulk production of FPs. The FPs were purified by iminobiotin chromatography as described (18), except that the loading pH was raised from 9.2 to 11 due to the reduced affinities of the mutant FPs for iminobiotin (33–35). Aggregates were reduced to approximately 3% by treatment with 20% dimethyl sulfoxide (DMSO). The eluted FPs were dialyzed against PBS at 4°C overnight and concentrated to 2.0 to 2.3 mg/mL using a YM30 membrane. The final FPs were filter-sterilized and stored in 5% sorbitol at 2.0 to 2.3 mg/mL using a YM30 membrane. The final FPs were filter-sterilized and stored in 5% sorbitol at −80°C. A negative control FP (CC49-WT-SAv) that recognizes the lactosamine residues and a single biotin residue per FPs (2.8 nmol) followed 24 hours later by i.v. injection of 125I was counted on a gamma counter. 125I activity and prevent spontaneous tumor regressions.

Blood clearance studies
Three groups of 4 athymic mice each were injected via the tail vein (i.v.) with 125I-1F5-Y43A-SAv or 125I-1F5-S45A-SAv FPs (2.8 nmol) followed 24 hours later by i.v. injection of 5.8 nmol of either NAGB or BBTG CA. Venous sampling was done via the tail vein at serial time points up to 68 hours. 125I was counted on a gamma counter and the percent of the injected dose per gram (%ID/g) of blood was calculated.

Mouse xenograft model
FoxN1™ athymic female mice (6–8 weeks old) were obtained from Harlan Sprague-Dawley and housed in the FHCR animal facility after approval of the experimental protocol by the Institutional Animal Care and Use Committee. Some groups of mice were switched to a biotin-deficient diet (Purina Mills) 5 to 6 days prior to PRIT studies. Ramos cells (10 × 10⁶) were injected subcutaneously in the right flank 10 days prior to experiments to produce lymphoma xenografts measuring 6 to 10 mm in diameter. Anti-asialoGM1 antiserum (30 µL, WAKO) was injected 9 days and 6 days prior to FP injection to abrogate natural killer cell activity and prevent spontaneous tumor regressions.

Biodistribution studies
Biodistribution experiments were done using the “double label” method of Pressman by trace labeling the 1F5-SAv FPs with 125I and the biotin moiety with 111In. In addition to independent assessment of tumor targeting of the FPs and the biotin ligands (36). Groups of 5 mice with similar-sized tumors were injected i.v. with 2.8 nmol (400 µg) of 1F5-WT-SAv, 1F5-Y43A-SAv, or 1F5-S45A-SAv FPs labeled with 20 to 40 µCi (0.74–1.48 MBq) of 125I. Twenty hours later, mice were injected with either 5.8 nmol of NAGB CA (50 µg) followed 4 hours later by 1.2 nmol DOTA-biotin labeled with 20 to 40 µCi (0.74–1.48 MBq) of 111In or with 5.8 nmol of BBTG CA (20 µg) followed 4 hours later by 1.2 nmol DOTA-biotin labeled with 20 to 40 µCi (0.74–1.48 MBq) of 111In.
nmol of $^{111}$In-DOTA-bis-biotin. Blood samples, tumors, and body organs were procured and $^{125}$I and $^{111}$In activities measured in a dual channel gamma counter, adjusting for crossover between channels (17).

**Therapy studies**

The therapeutic efficacy of $^{90}$Y using various pretargeted approaches was evaluated in groups of 5 to 10 mice. Groups of mice with similar sized, palpable tumors were selected and randomized for the studies. Mice were given 2.8 nmol (400 μg) of 1F5-WT-SAv, 1F5-Y43A-SAv, 1F5-S45A-SAv, or the negative control CC49-WT-SAv followed by 5.8 nmol of either NAGB or BBTG CA 20 hours later. A single dose of 1.2 nmol of either DOTA-biotin or DOTA-bis-biotin labeled with 500 μCi (18.5 MBq) $^{90}$Y was administered 4 hours after the CA. Mice were assessed every few days for tumor volume measurements, weight change, and general appearance. Mice were euthanized if xenografts exceeded 10% of total body weight, caused obvious discomfort or impaired ambulation, or if mice lost more than 30% of their baseline body weight.

**Toxicity studies**

Toxicity studies were done in parallel cohort groups, corresponding to the therapy groups. Mice were monitored for lethargy, poor grooming, weight loss and other behaviors consistent with debility. Blood testing was done 14 days after injection of $^{90}$Y, and at the time of euthanasia. Laboratory tests done included the leukocyte and platelet counts, hemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, and blood urea nitrogen (BUN) levels. Age-matched, untreated athymic mice were used for comparisons of hematology and chemistry data.

**Results**

**Expression and purification of WT-SAv and mutant-SAv FPs**

All FPs were successfully expressed in the periplasmic space of *E. coli* as soluble stable tetramers with molecular weights of approximately 174 KDa (Fig. 1). Expression levels for the FPs varied, with the S45A-SAv construct

![Figure 1. Schematization of the 1F5 scFv:SAv gene and its derivative tetravalent FP. A, the scFv:SAv fusion gene is comprised of the scFv gene of the murine anti-CD20 1F5 Ab fused to the full length SAv gene. B, a diagrammatic representation of the tetravalent FP that spontaneously forms after secretion into the periplasmic space of *E. coli*. C, representative HPLC tracing of a purified FP (S45A-SA); SDS-PAGE analyses of unpurified and iminobiotin-purified 1F5 (scFv):SAv WT FP (D), Y43A-SAv FP (E), and S45A-SAv FP (F), respectively. The mass of the intact FPs (174 KDa) and the monomers (44 KDa) are indicated on each SDS-PAGE gels (4%–12% Tris-glycine; Invitrogen) stained with Coomassie blue. Lane M, migration of prestained molecular weight standards (SeeBlue plus; Invitrogen). Lane 1, loaded *E. coli* crude lysate, containing 1F5(scFv):SAv WT FP. Lanes 2 and 3, flow-through and wash fractions, respectively, from an iminobiotin purification column. Lanes 4 and 5, iminobiotin-purified FP without boiling (lane 4) or denatured by boiling for 5 minutes to resolve the tetramers into monomers (lane 5).](http://clincancerres.aacrjournals.org/content/17/23/7376/F2.large.jpg)
producing the highest yield (358 mg/L), followed by Y43A-SAv (144 mg/L) and WT-SAv (100 mg/L; ref. 18). SDS-PAGE analysis confirmed purities of approximately 95% for the WT-SAv and mutant-SAv FPs after iminobiotin chromatography. All tetrameric FP bands resolved into a single species of MW ~ 44 kDa when the FPs were denatured by boiling before electrophoresis, consistent with a single protein entity dissociable into a homogeneous, monomeric subunit (Fig. 1).

**In vitro characterizations of mutant-SAv FPs**

Flow cytometry showed similar binding of the WT-SAv, S45A-SAv, and Y43A-SAv FPs and of the parental 1F5 antibody to CD20-expressing Ramos cells (Fig. 2). *In vitro* cell-binding assays were then done to compare the capture and retention of radiolabeled biotin moieties by FPs bound to CD20 on the surface of lymphoma cells (Fig. 3). As expected, the engineered low-affinity mutant FPs, 1F5-S45A-SAv and 1F5-Y43A-SAv, bound significantly less radiolabeled monovalent biotin (2.9 ± 0.003% and 4.9 ± 0.010% of the total 90Y activity presented to the cells, respectively) than did the WT-SAv FP (12.1 ± 0.02% of the 90Y activity added to the cultures). S45A-SAv and Y43A-SAv FPs were much more successful, as designed, in binding and retaining radiolabeled divalent bis-biotin (18.1 ± 0.005% and 17.4 ± 0.001% of applied 90Y activity, respectively). By comparison, WT-SAv FP bound 25.6 ± 0.02% of applied 90Y-labeled divalent bis-biotin. These results show that the divalent binding of the bis-biotin ligand compensated for the lower affinity of the Y43A and S45A mutant SAv molecules, yielding binding pairs at least comparable with the standard WT-SAv and monovalent DOTA-biotin reagents.

**Blood clearance studies**

The blood clearances of 125I-labeled mutant-SA FPs were evaluated after administration of CAs to athymic mice fed biotin-replete normal diets. Groups of 4 mice each were given 2.8 nmol of S45A-SAv or Y43A-SAv FP followed 20 hours later by divalent BBTG CA, monovalent NAGB CA, or PBS (negative control). A single injection of 5.8 nmol BBTG CA resulted in an approximately 80% decrease of circulating 125I-1F5-S45A-SAv within 30 minutes (shown logarithmically in Fig. 4) and an approximately 60% decrease in 125I-1F5-Y43A-SAv (not shown). In contrast, the monovalent biotin CA, NAGB, was ineffective at clearing the low affinity 125I-1F5-S45A-SAv or 125I-1F5-Y43A-SAv FPs from the blood, with clearances not significantly different from those seen in negative control mice treated with PBS (Fig. 4). These results show that the bis-biotin BBTG CA we designed works effectively as planned for the low affinity FPs, but that the standard NAGB CA, which possesses only a single biotin moiety, is ineffective for these constructs.

**Biodistribution studies**

Biodistribution experiments were conducted in mice with 1F5-Y43A-SAv, 1F5-S45A-SAv, and 1F5-WT-SAv FP and biotin compounds using the “dual label” method described previously. Groups of 5 athymic mice-bearing Ramos xenografts were injected i.v. with 400 μg (2.8 nmol) of 125I-labeled WT-SAv, Y43A-SAv, or S45A-SAv FPs followed 20 hours later by 5.8 nmol of BBTG or NAGB CA. Four hours later, mice were injected i.v. with 1.2 nmol of 111In-DOTA-bis-biotin or 111In-DOTA-biotin. Mice were euthanized 24 hours (Fig. 5A) or 48 hours (Fig. 5B) later and 125I and 111In were measured in excised tumors and normal organs using a dual channel gamma counter, adjusting for crossover of the 2 isotopes between channels. Biodistributions using the mutant-SA FPs did not include groups of mice on biotin-deficient diets because previous studies showed no differences in tumor uptake between mice on biotin-deficient diets.
counter. Control mice received 2.8 nmol of FPs without any CA (negative control) or to untreated cells incubated with PBS. Ramos cells (1.0 × 10^6 per sample) were incubated with 25 μL of 20 μg/mL 1F5-Y43A-SA v, 1F5-S45A-SA v, 1F5-WT-SA v, or CC49-WT-SA v (Figs. 3 and 6). Mice were treated with either mutant-SAv FPs or WT-SA v FP, except that radioactivity in blood and liver were slightly higher with mutant-SA v FPs, especially for Y43A-SA v (Fig. 5). The amount of radioactivity measured in tumors of mice fed normal diets treated with WT-SA v FP did not vary significantly whether 111In-DOTA-biotin or 111In-DOTA-bis-biotin was used, indicating that even the bis-biotin ligand was not able to displace prebound endogenous biotin from the biotin-binding sites of WT-SA v. Overall, the combination of mutant-SA v FPs, BBTG CA, and DOTA-bis-biotin resulted in superior biodistributions of radioactivity compared with conventional WT-SA v FP, NAGB CA, and DOTA-biotin in mice fed normal diets, where endogenous biotin levels are known to be high.

**Therapy and toxicity studies**

Therapy studies compared the efficacy of 90Y-labeled biotin compounds for treating lymphoma xenografts in mice pretargeted with the WT and mutant SA v FPs or with a nonbinding negative control, CC49-WT-SA v FP (Fig. 6). Mice were assigned into 6 different groups and fed either a biotin-deficient diet or a regular biotin-containing diet. The median tumor size was 86 ± 42 mm^3 at the initiation of the study with no significant differences between groups. Mice were treated with WT-SA v, S45A-SA v, Y43A-SA v, or CC49-WT-SA v FPs followed 20 hours later by either NAGB or BBTG CA. A single injection of 500 μCi [90Y]-labeled DOTA-bis-biotin or monovalent DOTA-biotin was given 4 hours after the CA injection. Animals on a regular diet that received Y43A-SA v and S45A-SA v FPs had mean tumor volumes of 236 ± 66 mm^3 and 543 ± 320 mm^3 11 days after therapy, respectively, compared with 1435 ± 212 mm^3 for mice that received a nonbinding diet and normal diets with mutant SA v conjugates (29). There were no significant differences in tumor or normal organ biodistributions of 125I in groups given mutant-SA v or WT-SA v FPs at either 24 or 48 hours, indicating that all the anti-CD20 FPs have similar tumor targeting and tissue biodistributions (Supplementary Fig. S1). Analyses of the biodistributions of 111In-labeled biotin compounds indicated that 111In-DOTA-bis-biotin was effectively targeted to tumors in mice pretargeted with mutant-SA v FPs even when mice were fed normal biotin-containing diets, whereas monovalent 111In-DOTA-biotin was not effectively tar-
control CC49-SAv FP ($P < 0.0001$) and $1129 \pm 322 \text{ mm}^3$ for animals that received WT-SAv FP ($P < 0.03$). Administration of WT-SAv FP to mice fed a biotin-deficient diet was associated with the most significant delay in tumor growth ($11 \pm 22 \text{ mm}^3$ at day 11). Treatment was well tolerated with no evidence of acute toxicity. Complete blood counts, creatinine, and transaminase levels 14 days after therapy were similar in all groups of mice except that mildly lower leukocyte counts were observed in mice in all of the treatment groups compared with control, untreated mice (Supplementary Table S2).

**Discussion**

The efficacy of RIT in patients with NHL has been established by a multitude of clinical trials, but the majority of patients treated with nonmyeloablative doses of RIT eventually relapse (37–38). PRIT using SAv-biotin methodology has emerged as one promising approach to deliver potentially curative radiation doses to tumors while minimizing toxicities arising from the nonspecific radiation delivered to normal organs. Although the high affinity of SAv for biotin is essential for this pre-targeting system, this tight interaction
can paradoxically present a significant limitation when naturally occurring endogenous biotin irreversibly blocks the SAv-binding sites, decreases the capacity of SAv to bind radiolabeled DOTA-biotin, and reduces therapeutic efficacy. Although short-term biotin-depletion can be routinely achieved in mouse models, rigorous biotin-depletion is difficult in clinical settings due to its ubiquitous presence in all common foods. Even if endogenous biotin is successfully depleted, suboptimal targeting may still occur because the extremely slow “off rate” of radiobiotin hinders its diffusion to the center of tumor masses, due to “trapping” of radiobiotin in perivascular or peripheral locations by irreversible, high-affinity binding to the most accessible tumor cells. Computer models and experimental data have verified that such a “binding-site barrier” does exist and may compromise therapeutic efficacy of radioimmunoconjugates of extremely high-binding affinities, though this problem can be at least partially overcome by administration of a large excess of Ab-SAv conjugate and radiobiotin (39–40).

In this study, we show the potential advantage of a novel, engineered PRIT system utilizing mutant-SAv FPs and bivalent radiolabeled DOTA-bis-biotin for treatment of lymphomas in situations where endogenous biotin may limit the effectiveness of standard SAv-biotin PRIT. Our group has previously shown that specific delivery of high doses of radiation to tumor sites is achievable even in the presence of endogenous biotin using chemical conjugates of 1F5 Ab and mutant-SAv protein produced using heterobifunctional cross-linkers in combination with bivalent biotin ligands (28–29). Here, we describe the genetic engineering, expression, in vitro characterization, and in vivo testing of novel 1F5-mutant-SAv FPs, which are more homogeneous, more amenable to scale-up, and less costly to manufacture than the previously described Ab-mutant-SAv chemical conjugates (33).

We have produced anti-CD20 mutant-SAv FPs that maintain the full antigen-binding capacity of the parent monoclonal Ab, but have a reduced avidity for endogenous biotin compared with WT-SAv FP. We selected the Y43A and S45A mutants for incorporation into scFv-SAvaFPs from a panel of available mutants produced by site-directed mutagenesis based on prior in vitro assays, which suggested that these particular mutations would be most advantageous (27, 29). The Y43A-SAv and S45A-SAv mutant molecules have 67- and 907-fold lower affinity for biotin, respectively, compared with WT-SAv, but retain robust binding to divalent biotin compounds, as shown by their significantly slower off-rates for bis-biotin than biotin (27). Mutant-SAv FPs were directly compared with WT-SAv FP using a cell-binding assay (Fig. 3), which showed that both Y43A-SAv and S45A-SAv FPs have significantly lower affinity for monovalent biotin compared with WT-SAv FP, but have sufficiently high affinity to efficiently capture bis-biotin ligands. These in vitro results suggest that the lower affinity of the mutant-SAv FPs for monovalent biotin may allow prebound endogenous monovalent biotin to quickly dissociate, yet permit the durable capture and retention of radiolabeled divalent bis-biotin ligands by mutant-SAv FPs. To utilize this mutant-SAv FP and bis-biotin system effectively, a synthetic trigalactose-containing bis-biotin CA was conceptualized and generated by our group to facilitate blood clearance of the mutant-SAv FPs (28).

Pharmacokinetic experiments showed that treatment of mice with BBTG CA resulted in efficient clearance of mutant-SAv FPs from the blood. As expected, the standard CA containing a single biotin moiety (NAGB) had a negligible effect on the blood clearance of the mutant-SAv FPs.

Biodistribution experiments confirmed that the uptake and retention of radiolabeled DOTA-biotin by WT-SAv FP was significantly compromised at tumor sites when animals were fed a regular diet, presumably because of the deleterious impact of endogenous biotin blocking the biotin-binding sites of SAv. In marked contrast, the mutant-SAv FPs exhibited excellent tumor retention of radiolabeled DOTA-bis-biotin even in animals fed a regular biotin-rich diet. The amounts of radioactivity in normal tissues were similar in mice treated with mutant-SAv and WT-SAv FPs, except for the blood and liver, which contained slightly more radioactivity in groups treated with mutant-SAv than in mice treated with WT-SAv and NAGB CA. We presume these differences emerged because the BBTG CA was less efficient at clearing mutant-SAv FPs from the blood than the NAGB CA was at clearing WT-SAv (17, 41). Therefore, further optimization of the bis-biotin CA is planned using variations in the galactose content of the molecule.

In therapy experiments, mutant-SAv FPs in combination with 90Y-DOTA-bis-biotin produced significant tumor growth delays in mice bearing lymphoma xenografts fed biotin-replete normal diets while the standard regimen, utilizing WT-SAv and 90Y-DOTA-biotin, had no significant effect on tumor growth in the presence of endogenous biotin. These data support the hypothesis that mutant-SAv FPs with optimized biotin-binding affinities can improve the amount of radiation delivered specifically to tumor sites.
compared with WT-SA FP in the presence of competing endogenous biotin.

Although it must be acknowledged that the current gold standard combination of WT-SA FP and radiolabeled DOTA-biotin remains superior in situations where rigorous biotin depletion can be achieved, these studies show the promise of such a genetically engineered PRIT system for situations where endogenous biotin may limit its efficacy through competitive inhibition at the SAv-binding site. In addition, it is conceivable that the SAv mutants used in these experiments may not possess the optimal off-rates for biotin and bis-biotin to maximize tumor retention. Therefore, additional mutant-SAv FPs will be engineered and tested to further optimize the affinity and off-rate for monovalent biotin and bivalent biotin ligands.

We acknowledge that one potential limitation of SAv-biotin pretargeting systems is the immunogenicity of SAv (and of murine Ab). Although human anti-mouse Ab (HAMA) and human anti-SAv Ab (HASA) may be major limitations for applications in immunocompetent patients and for experimental regimens requiring repetitive rounds of therapy, we do not anticipate that immunogenicity will be a major limitation for this approach in patients with advanced leukemia and lymphoma, who are the focus of our investigations. We have administered RIT using murine Ab to 476 patients with non-Hodgkin lymphoma or acute myeloid leukemia at our center since 1987. Only 14 of these 476 patients (2.9%) formed HAMA between the dosimetric and therapeutic infusions of radiolabeled Ab. Furthermore, we recently opened a clinical trial of PRIT using a murine anti-CD45 Ab with SAv and radiolabeled biotin for patients with acute myeloid leukemia (ClinicalTrials.gov identifier NCT00988715; IND # 104683). No immune responses to either Ab or SAv have yet been detected in the 5 patients treated, presumably due to the compromised immune system of these patients (unpublished data). HASA have also not been major impediments in published studies of lymphoma patients treated with streptavidin-biotin PRIT by others (19, 22). We believe that our ongoing trial, and previous RIT studies by others, show that Ab-SA PRIT approaches are translatable to the clinic.

In summary, we have shown the potential of rationally engineered mutant-SAv FPs to be used in conjunction with divalent bis-biotin CA and bis-biotin radioisotope carriers to circumvent the potential blocking effects of endogenous biotin. This approach may allow the effective delivery of higher doses of radiation to tumor sites than is possible with standard SAv-biotin PRIT systems in settings where rigorous biotin depletion is not feasible.

Disclosure of Potential Conflicts of Interest

O.W. Press has received honoraria for consultation from Algeta, Roche/Genentech, Spectrum Pharmaceuticals, and Seattle Genetics and research support from Roche/Genentech. A.K. Gopal has received honoraria for lectures from Seattle Genetics and Millennium and research support from Glaxo Smith Kline, Merck, Cephalon, Piramal, Pfizer, Abbott, BioMarin, Seattle Genetics, Eli Lilly, and Spectrum Pharmaceuticals. J.M. Pagel has research support from Glaxo Smith Kline. The other authors disclosed no potential conflicts of interest.

Authors' Contributions

S.I. Park designed and performed research, analyzed data, and drafted the manuscript. J. Shenoi designed and performed research, analyzed data, and drafted the manuscript. S. Frayo performed research, collected data, and analyzed data. D.K. Hamlin contributed vital reagents and performed research. Y. Lin engineered, expressed, purified, and tested the fusion proteins. P.S. Stastny produced the mutant streptavidin gene constructs by directed mutagenesis. D.S. Wilbur contributed to the conception, design, analysis, and interpretation of research. N. Organ, A. Kenoyer, and A. Axtman performed research and collected data. M. Hylaines contributed vital reagents, design and interpretation of research. F. Buchegger performed research and analyzed data. A.K. Gopal and D.J. Green contributed to the interpretation of data. J.M. Pagel contributed to the conception, design, analysis, and interpretation of research and edited the manuscript. O.W. Press contributed to the conception, design, analysis and interpretation of research, revised the manuscript, and funded the experiments.

Grant Support

This work was supported by grants from the NIH: RO1 CA076287, PO1 CA44991, and the Lymphoma Research Foundation and gifts from David and Patricia Gaidani, Mary and Geary Britton-Simmons, James and Sherry Raisbeck, the Wyner-Stokes Foundation, and the Hext Family Foundation. A.K. Gopal is a scholar in clinical research of the Leukemia and Lymphoma Society. S.I. Park is a recipient of a Lymphoma Research Foundation Fellowship Award.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 10, 2011; revised July 23, 2011; accepted September 21, 2011; published OnlineFirst October 5, 2011.

References

   et al. High–dose radioimmunotherapy versus conventional high-
   dose therapy and autologous hematopoietic cell transplantation for
   relapsed follicular non-Hodgkin lymphoma: a multinational cohort
9. Press OW, Eary JF, Applebaum FR, Martin PJ, Badger CC, Nelp WB,
   et al. Radiolabeled-antibody therapy of B-cell lymphoma with autol-
    phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide,
    cyclophosphamide, and autologous stem cell transplantation for
11. Goodwin DA, Meares CF, Osen M. Biological properties of biotin-
    chelate conjugates for pretargeted diagnosis and therapy with the
12. Rosebrough SF. Pharmacokinetics and biodistribution of radiolabeled
13. Paganeli G, Malcovati M, Fazio F. Monoclonal antibody pretargeting
    techniques for tumour localization: the avidin-biotin system. Interna-
    tional Workshop on Techniques for Amplification of Tumour Target-
15. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and
16. Axworthy DB, Reno JM, Hyalaires MD, Mallett RW, Theodore LJ,
    dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad
17. Press OW, Concoran M, Subbahl K, Hamlin DK, Wilbur DS, Johnson T,
    et al. A comparative evaluation of conventional and pretargeted radio-
    immunoconjugate therapy utilizing monoclonal antibody-based
18. Lin Y, Pagel JM, Axworthy D, Pantellas A, Hedni N, Press OW. A
    genetically engineered anti-CD45 single-chain antibody-streptavidin
    fusion protein for pretargeted radioimmunotherapy of hematologic
    644–50.
    M, et al. Durable responses after ibritumomab tiuxetan radioimmu-
    notherapy for CD20+ B-cell lymphoma: long-term follow-up of a
tetavalent single-chain antibody-streptavidin fusion protein for pre-
    644–50.
23. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis
    of monoclonal antibody percolation through tumors: a binding-site
    Comparison of anti-CD20 and anti-CD45 antibodies for conventional
    and pretargeted radioimmunotherapy of B-cell lymphomas. Blood
Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Steven I. Park, Jaideep Shenoi, Shani M. Frayo, et al.

Clin Cancer Res 2011;17:7373-7382. Published OnlineFirst October 5, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-1204

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2011/10/05/1078-0432.CCR-11-1204.DC1

Cited articles
This article cites 41 articles, 22 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/17/23/7373.full.html#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
/content/17/23/7373.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.